ID

39090

Description

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02268045

Link

https://clinicaltrials.gov/show/NCT02268045

Keywords

Versions (1)
  1. 11/30/19 11/30/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 30, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diffuse Large B-cell Lymphoma NCT02268045

English

Eligibility Diffuse Large B-cell Lymphoma NCT02268045

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with measurable disease defined as existence of a unidimensional or bidimensional lesion greater than 2 cm in its longest diameter or malignant lymphocytosis greater than 5x109/l. any other procedure for measurable disease in particular cases, may be allowed upon sponsor approval
Description

Measurable Disease | Lesion Linear Longest Diameter | Lesion 2-Dimensional Longest Diameter | Lymphocytosis Malignant Measurement

Data type

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C0221198
UMLS CUI [2,2]
C0205132
UMLS CUI [2,3]
C0552406
UMLS CUI [3,1]
C0221198
UMLS CUI [3,2]
C1705052
UMLS CUI [3,3]
C0552406
UMLS CUI [4,1]
C0024282
UMLS CUI [4,2]
C0205282
UMLS CUI [4,3]
C0242485
2. newly diagnosed patients with a confirmed pathologic diagnosis of large b cell-non-hodgkin's lymphoma (dlbcl) with untreated cd20+. defined by the local haematopathologist at the local laboratory according to who criteria
Description

Diffuse Large B-Cell Lymphoma CD20 positive WHO tumor classification | Diffuse Large B-Cell Lymphoma CD20 positive Untreated

Data type

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C3888518
UMLS CUI [1,3]
C1301142
UMLS CUI [2,1]
C0079744
UMLS CUI [2,2]
C3888518
UMLS CUI [2,3]
C0332155
3. stage ii-iii or iv or stage i with bulk defined by the referring physician on the basis of the cotswolds modification of the ann arbor classification 2
Description

Cotswolds Hodgkin's disease tumor staging system

Data type

boolean

Alias
UMLS CUI [1]
C0474950
4. age-adjusted international prognostic index (ipi) score 0 or 1
Description

International Prognostic Index adjusted for age

Data type

boolean

Alias
UMLS CUI [1,1]
C1512894
UMLS CUI [1,2]
C4300468
5. age ≥18 to ≤65 years of age
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
6. performance status (eastern cooperative oncology group [ecog]) of ≤2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
7. written informed consent obtained before starting any study-specific procedure
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
8. females of child-bearing potential must test negative on standard serum pregnancy test and must be willing to practice appropriate contraceptive methods for the duration of the study (e.g. oral contraceptive, double barrier method, intra-uterine device, intra-muscular contraceptive)
Description

Childbearing Potential Serum pregnancy test negative | Childbearing Potential Contraceptive methods | Contraceptives, Oral | Barrier Contraception Double | Intrauterine Devices | Intramuscular injection for birth control

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430061
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C0009905
UMLS CUI [4,1]
C0004764
UMLS CUI [4,2]
C0205173
UMLS CUI [5]
C0021900
UMLS CUI [6]
C2078149
9. all male patients must take adequate contraceptive precautions during the course of the study
Description

Gender Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. life expectancy of less than three months
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
2. any other lymphoma other than cd20+ dlbcl
Description

Lymphoma | Exception Diffuse Large B-Cell Lymphoma CD20 antigen positive

Data type

boolean

Alias
UMLS CUI [1]
C0024299
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0079744
UMLS CUI [2,3]
C3888518
3. indolent lymphoma, primary central nervous system (cns) lymphoma or gastro-intestinal mucosa associated lymphoid tissue (malt) lymphoma
Description

Indolent Lymphoma | Primary central nervous system lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C1334170
UMLS CUI [2]
C0280803
UMLS CUI [3]
C0242647
4. known hypersensitivity to active ingredients, excipients and murine and foreign proteins
Description

Hypersensitivity Active ingredient | Hypersensitivity Pharmaceutical Excipient | Hypersensitivity Murine protein | Hypersensitivity FOREIGN PROTEIN INJECTION

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1292749
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0015237
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1699668
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0239684
5. concurrent disease or general status that would exclude giving the treatment as outlined in the protocol
Description

Comorbidity Excludes Treatment Protocol | General status Excludes Treatment Protocol

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0040808
UMLS CUI [2,1]
C0947124
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0040808
6. active uncontrolled infection requiring systemic treatment with antibiotics or antiviral agents at screening or history of documented recurrent clinically significant infection (e.g. 2 or more viral, bacterial or fungal infections requiring inpatient treatment)
Description

Communicable Disease Uncontrolled | Requirement Antibiotic therapy Systemic | Requirement Antiviral Agents Systemic | Recurrent infections | Virus Diseases Quantity | Bacterial Infections Quantity | Mycoses Quantity | Hospitalization Required

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C1514873
UMLS CUI [2,2]
C0338237
UMLS CUI [2,3]
C0205373
UMLS CUI [3,1]
C1514873
UMLS CUI [3,2]
C0003451
UMLS CUI [3,3]
C0205373
UMLS CUI [4]
C0239998
UMLS CUI [5,1]
C0042769
UMLS CUI [5,2]
C1265611
UMLS CUI [6,1]
C0004623
UMLS CUI [6,2]
C1265611
UMLS CUI [7,1]
C0026946
UMLS CUI [7,2]
C1265611
UMLS CUI [8]
C1708385
7. cardiac contra-indication to doxorubicin therapy: non-compensated heart failure, dilated cardiomyopathy, coronary heart disease with st segment depression on electrocardiogram (ecg), myocardial infarction in the last 6 months
Description

Medical contraindication Cardiac Doxorubicin | Decompensated cardiac failure | Cardiomyopathy, Dilated | Coronary heart disease | ST segment depression ECG | Myocardial Infarction

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0018787
UMLS CUI [1,3]
C0013089
UMLS CUI [2]
C0581377
UMLS CUI [3]
C0007193
UMLS CUI [4]
C0010068
UMLS CUI [5,1]
C0520887
UMLS CUI [5,2]
C1623258
UMLS CUI [6]
C0027051
8. neurologic contra-indication to vincristine as it is indicated in the smpc: (e.g. peripheral neuropathy)
Description

Medical contraindication Neurologic Vincristine | Peripheral Neuropathy

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0205494
UMLS CUI [1,3]
C0042679
UMLS CUI [2]
C0031117
9. chronic lung disease with hypoxemia measured by saturometer (gasometry is not mandatory)
Description

Chronic lung disease | Hypoxemia Measurement | Other Coding

Data type

boolean

Alias
UMLS CUI [1]
C0746102
UMLS CUI [2,1]
C0700292
UMLS CUI [2,2]
C0242485
UMLS CUI [3]
C3846158
10. severe uncontrolled hypertension, despite optimal medical treatment
Description

Uncontrolled hypertension Severe | Treatment Optimal

Data type

boolean

Alias
UMLS CUI [1,1]
C1868885
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C2698651
11. severe uncontrolled diabetes mellitus, despite optimal medical treatment
Description

Uncontrolled diabetes mellitus Severe | Treatment Optimal

Data type

boolean

Alias
UMLS CUI [1,1]
C0421258
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C2698651
12. renal insufficiency (serum creatinine>2xunl)
Description

Renal Insufficiency | Serum creatinine raised

Data type

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0700225
13. hepatic insufficiency (aspartate aminotransferase [ast]/alanine aminotransferase [alt] >3xunl or >5xunl with involvement of the liver, total bilirubin >34.2 µmol/l, or both) not related to lymphoma
Description

Hepatic Insufficiency Independent of Lymphoma | Aspartate aminotransferase increased | Alanine aminotransferase increased | Involvement with Liver | Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1306571
UMLS CUI [1,2]
C0332291
UMLS CUI [1,3]
C0024299
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0151905
UMLS CUI [4,1]
C1314939
UMLS CUI [4,2]
C0023884
UMLS CUI [5]
C1278039
14. clinical signs of cerebral dysfunction
Description

Sign or Symptom Cerebral dysfunction

Data type

boolean

Alias
UMLS CUI [1,1]
C3540840
UMLS CUI [1,2]
C0262405
15. severe psychiatric disease
Description

Mental Disorder, Severe

Data type

boolean

Alias
UMLS CUI [1]
C4046029
16. known human immunodeficiency virus (hiv) infection or active chronic hepatitis b or c
Description

HIV Infection | Hepatitis B, Chronic | Hepatitis C, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0524909
UMLS CUI [3]
C0524910
17. abnormal bone marrow function (platelets <100x109/l, neutrophils <1.5x109/l and haemoglobin <9g/dl)
Description

Bone Marrow function Abnormal | Platelet Count measurement | Neutrophil count | Hemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [1,3]
C0205161
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0200633
UMLS CUI [4]
C0518015
18. post-transplantation lymphoproliferative disease
Description

Post-transplant lymphoproliferative disease

Data type

boolean

Alias
UMLS CUI [1]
C2367985
19. pregnant or lactating women or women that intend to get pregnant during study or within 12 months following the last infusion
Description

Pregnancy | Breast Feeding | Pregnancy intended

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0032961
UMLS CUI [3,2]
C1283828
20. treatment with any investigational product in the 30 days period before inclusion in the study
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
21. prior radiotherapy to treat the dlbcl nhl
Description

Prior radiation therapy Diffuse Large B-Cell Lymphoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0079744
22. limitation of the patient's ability to comply with the treatment or follow-up protocol
Description

Protocol Compliance Limited

Data type

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C0439801
Back to the top of the page

Similar models

Eligibility Diffuse Large B-cell Lymphoma NCT02268045

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Measurable Disease | Lesion Linear Longest Diameter | Lesion 2-Dimensional Longest Diameter | Lymphocytosis Malignant Measurement
Item
1. patients with measurable disease defined as existence of a unidimensional or bidimensional lesion greater than 2 cm in its longest diameter or malignant lymphocytosis greater than 5x109/l. any other procedure for measurable disease in particular cases, may be allowed upon sponsor approval
boolean
C1513041 (UMLS CUI [1])
C0221198 (UMLS CUI [2,1])
C0205132 (UMLS CUI [2,2])
C0552406 (UMLS CUI [2,3])
C0221198 (UMLS CUI [3,1])
C1705052 (UMLS CUI [3,2])
C0552406 (UMLS CUI [3,3])
C0024282 (UMLS CUI [4,1])
C0205282 (UMLS CUI [4,2])
C0242485 (UMLS CUI [4,3])
Diffuse Large B-Cell Lymphoma CD20 positive WHO tumor classification | Diffuse Large B-Cell Lymphoma CD20 positive Untreated
Item
2. newly diagnosed patients with a confirmed pathologic diagnosis of large b cell-non-hodgkin's lymphoma (dlbcl) with untreated cd20+. defined by the local haematopathologist at the local laboratory according to who criteria
boolean
C0079744 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C1301142 (UMLS CUI [1,3])
C0079744 (UMLS CUI [2,1])
C3888518 (UMLS CUI [2,2])
C0332155 (UMLS CUI [2,3])
Cotswolds Hodgkin's disease tumor staging system
Item
3. stage ii-iii or iv or stage i with bulk defined by the referring physician on the basis of the cotswolds modification of the ann arbor classification 2
boolean
C0474950 (UMLS CUI [1])
International Prognostic Index adjusted for age
Item
4. age-adjusted international prognostic index (ipi) score 0 or 1
boolean
C1512894 (UMLS CUI [1,1])
C4300468 (UMLS CUI [1,2])
Age
Item
5. age ≥18 to ≤65 years of age
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
6. performance status (eastern cooperative oncology group [ecog]) of ≤2
boolean
C1520224 (UMLS CUI [1])
Informed Consent
Item
7. written informed consent obtained before starting any study-specific procedure
boolean
C0021430 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Contraceptive methods | Contraceptives, Oral | Barrier Contraception Double | Intrauterine Devices | Intramuscular injection for birth control
Item
8. females of child-bearing potential must test negative on standard serum pregnancy test and must be willing to practice appropriate contraceptive methods for the duration of the study (e.g. oral contraceptive, double barrier method, intra-uterine device, intra-muscular contraceptive)
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0009905 (UMLS CUI [3])
C0004764 (UMLS CUI [4,1])
C0205173 (UMLS CUI [4,2])
C0021900 (UMLS CUI [5])
C2078149 (UMLS CUI [6])
Gender Contraceptive methods
Item
9. all male patients must take adequate contraceptive precautions during the course of the study
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Life Expectancy
Item
1. life expectancy of less than three months
boolean
C0023671 (UMLS CUI [1])
Lymphoma | Exception Diffuse Large B-Cell Lymphoma CD20 antigen positive
Item
2. any other lymphoma other than cd20+ dlbcl
boolean
C0024299 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0079744 (UMLS CUI [2,2])
C3888518 (UMLS CUI [2,3])
Indolent Lymphoma | Primary central nervous system lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma
Item
3. indolent lymphoma, primary central nervous system (cns) lymphoma or gastro-intestinal mucosa associated lymphoid tissue (malt) lymphoma
boolean
C1334170 (UMLS CUI [1])
C0280803 (UMLS CUI [2])
C0242647 (UMLS CUI [3])
Hypersensitivity Active ingredient | Hypersensitivity Pharmaceutical Excipient | Hypersensitivity Murine protein | Hypersensitivity FOREIGN PROTEIN INJECTION
Item
4. known hypersensitivity to active ingredients, excipients and murine and foreign proteins
boolean
C0020517 (UMLS CUI [1,1])
C1292749 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0015237 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C1699668 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0239684 (UMLS CUI [4,2])
Comorbidity Excludes Treatment Protocol | General status Excludes Treatment Protocol
Item
5. concurrent disease or general status that would exclude giving the treatment as outlined in the protocol
boolean
C0009488 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0040808 (UMLS CUI [1,3])
C0947124 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0040808 (UMLS CUI [2,3])
Communicable Disease Uncontrolled | Requirement Antibiotic therapy Systemic | Requirement Antiviral Agents Systemic | Recurrent infections | Virus Diseases Quantity | Bacterial Infections Quantity | Mycoses Quantity | Hospitalization Required
Item
6. active uncontrolled infection requiring systemic treatment with antibiotics or antiviral agents at screening or history of documented recurrent clinically significant infection (e.g. 2 or more viral, bacterial or fungal infections requiring inpatient treatment)
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C1514873 (UMLS CUI [2,1])
C0338237 (UMLS CUI [2,2])
C0205373 (UMLS CUI [2,3])
C1514873 (UMLS CUI [3,1])
C0003451 (UMLS CUI [3,2])
C0205373 (UMLS CUI [3,3])
C0239998 (UMLS CUI [4])
C0042769 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C0004623 (UMLS CUI [6,1])
C1265611 (UMLS CUI [6,2])
C0026946 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
C1708385 (UMLS CUI [8])
Medical contraindication Cardiac Doxorubicin | Decompensated cardiac failure | Cardiomyopathy, Dilated | Coronary heart disease | ST segment depression ECG | Myocardial Infarction
Item
7. cardiac contra-indication to doxorubicin therapy: non-compensated heart failure, dilated cardiomyopathy, coronary heart disease with st segment depression on electrocardiogram (ecg), myocardial infarction in the last 6 months
boolean
C1301624 (UMLS CUI [1,1])
C0018787 (UMLS CUI [1,2])
C0013089 (UMLS CUI [1,3])
C0581377 (UMLS CUI [2])
C0007193 (UMLS CUI [3])
C0010068 (UMLS CUI [4])
C0520887 (UMLS CUI [5,1])
C1623258 (UMLS CUI [5,2])
C0027051 (UMLS CUI [6])
Medical contraindication Neurologic Vincristine | Peripheral Neuropathy
Item
8. neurologic contra-indication to vincristine as it is indicated in the smpc: (e.g. peripheral neuropathy)
boolean
C1301624 (UMLS CUI [1,1])
C0205494 (UMLS CUI [1,2])
C0042679 (UMLS CUI [1,3])
C0031117 (UMLS CUI [2])
Chronic lung disease | Hypoxemia Measurement | Other Coding
Item
9. chronic lung disease with hypoxemia measured by saturometer (gasometry is not mandatory)
boolean
C0746102 (UMLS CUI [1])
C0700292 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C3846158 (UMLS CUI [3])
Uncontrolled hypertension Severe | Treatment Optimal
Item
10. severe uncontrolled hypertension, despite optimal medical treatment
boolean
C1868885 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C2698651 (UMLS CUI [2,2])
Uncontrolled diabetes mellitus Severe | Treatment Optimal
Item
11. severe uncontrolled diabetes mellitus, despite optimal medical treatment
boolean
C0421258 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C2698651 (UMLS CUI [2,2])
Renal Insufficiency | Serum creatinine raised
Item
12. renal insufficiency (serum creatinine>2xunl)
boolean
C1565489 (UMLS CUI [1])
C0700225 (UMLS CUI [2])
Hepatic Insufficiency Independent of Lymphoma | Aspartate aminotransferase increased | Alanine aminotransferase increased | Involvement with Liver | Serum total bilirubin measurement
Item
13. hepatic insufficiency (aspartate aminotransferase [ast]/alanine aminotransferase [alt] >3xunl or >5xunl with involvement of the liver, total bilirubin >34.2 µmol/l, or both) not related to lymphoma
boolean
C1306571 (UMLS CUI [1,1])
C0332291 (UMLS CUI [1,2])
C0024299 (UMLS CUI [1,3])
C0151904 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
C1314939 (UMLS CUI [4,1])
C0023884 (UMLS CUI [4,2])
C1278039 (UMLS CUI [5])
Sign or Symptom Cerebral dysfunction
Item
14. clinical signs of cerebral dysfunction
boolean
C3540840 (UMLS CUI [1,1])
C0262405 (UMLS CUI [1,2])
Mental Disorder, Severe
Item
15. severe psychiatric disease
boolean
C4046029 (UMLS CUI [1])
HIV Infection | Hepatitis B, Chronic | Hepatitis C, Chronic
Item
16. known human immunodeficiency virus (hiv) infection or active chronic hepatitis b or c
boolean
C0019693 (UMLS CUI [1])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
Bone Marrow function Abnormal | Platelet Count measurement | Neutrophil count | Hemoglobin measurement
Item
17. abnormal bone marrow function (platelets <100x109/l, neutrophils <1.5x109/l and haemoglobin <9g/dl)
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,3])
C0032181 (UMLS CUI [2])
C0200633 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
Post-transplant lymphoproliferative disease
Item
18. post-transplantation lymphoproliferative disease
boolean
C2367985 (UMLS CUI [1])
Pregnancy | Breast Feeding | Pregnancy intended
Item
19. pregnant or lactating women or women that intend to get pregnant during study or within 12 months following the last infusion
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C1283828 (UMLS CUI [3,2])
Investigational New Drugs
Item
20. treatment with any investigational product in the 30 days period before inclusion in the study
boolean
C0013230 (UMLS CUI [1])
Prior radiation therapy Diffuse Large B-Cell Lymphoma
Item
21. prior radiotherapy to treat the dlbcl nhl
boolean
C0279134 (UMLS CUI [1,1])
C0079744 (UMLS CUI [1,2])
Protocol Compliance Limited
Item
22. limitation of the patient's ability to comply with the treatment or follow-up protocol
boolean
C0525058 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial